The Patent Finder

Sygnis Bioscience GmbH & Co. KG

Also on record
Records under this name other than patents Sygnis Bioscience GmbH & Co. KG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Sygnis Bioscience GmbH & Co. KG

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,349,619Method for detecting and analyzing protein interactions in-vivo
Term ended
Term ended May 4, 2024 · USPTO record
Term endedTerm ended May 4, 2024USPTO record
US 7,785,601Methods of treating neurological conditions with hematopoietic growth factors
Formerly held
Lapsed on the fee record
Ended Aug 31, 2022 · USPTO record
Lapsed on the fee recordEnded Aug 31, 2022USPTO record
US 8,071,543Methods of treating neurological conditions with hematopoeitic growth factors
Formerly held
Lapsed on the fee record
Ended Dec 6, 2019 · USPTO record
Lapsed on the fee recordEnded Dec 6, 2019USPTO record
US 8,053,407Methods of treating neurological conditions with hematopoeitic growth factors
Formerly held
Lapsed on the fee record
Ended Nov 8, 2019 · USPTO record
Lapsed on the fee recordEnded Nov 8, 2019USPTO record
US 7,884,069Methods of treating neurological conditions with hematopoeitic growth factors
Formerly held
Lapsed on the fee record
Ended Feb 8, 2019 · USPTO record
Lapsed on the fee recordEnded Feb 8, 2019USPTO record
US 7,695,723Methods of treating neurological conditions with hematopoietic growth factors
Formerly held
Lapsed on the fee record
Ended Apr 13, 2018 · USPTO record
Lapsed on the fee recordEnded Apr 13, 2018USPTO record
US 7,585,635Method for detecting and analyzing protein interactions in vivo
Lapsed on the fee record
Ended Sep 8, 2017 · USPTO record
Lapsed on the fee recordEnded Sep 8, 2017USPTO record
US 7,361,502Nucleic acid molecule encoding a neuronal serine-threonine protein kinase
Lapsed on the fee record
Ended Apr 22, 2016 · USPTO record
Lapsed on the fee recordEnded Apr 22, 2016USPTO record
US 7,361,681Method of treating amytrophic lateral sclerosis using melatonin
Lapsed on the fee record
Ended Apr 22, 2016 · USPTO record
Lapsed on the fee recordEnded Apr 22, 2016USPTO record
US 7,575,857Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
Lapsed on the fee record
Ended Aug 18, 2013 · USPTO record
Lapsed on the fee recordEnded Aug 18, 2013USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited